Cantargia Ab · OMXSTO:CANTA
Cantargia Ab — Sedermera Dagen 2018
18 slides from Cantargia Ab's conference presentation, May 15, 2018
Slide 1: We want to save patients with severe cancer and autoimmune diseases
We want to save patients with severe cancer and autoimmune diseases Entering clinical phase with our lead antibody CAN04 to our proprietary target Göran Forsberg, CEO 1
Slide 2: Safe Harbour Statement
Safe Harbour Statement The following presentation may include predictions, estimates or other information that might be considered forward-looking. The statements regarding the surrounding world and future circumstances in this presentation reflect Cantargia’s current thinking with respect to future
Slide 3: CANTOS IL-1β blockade - Recent strong clinical data
CANTOS IL-1β blockade - Recent strong clinical data CANTOS trial • Canakinumab (Novartis) • 10 061 patients • Designed to reduce Placebo cardiovascular events in patients with previous myocardial infarction • Reduced lung cancer incidence by 67 % and death by 77 %. High dose • Clinical validation of
Slide 4: CAN04 vs Canakinumab
CAN04 vs Canakinumab IL-1b Canakinumab IL-1a IL-33 • Antibody directed against one of the two IL-1 ligands, IL-1β CAN04: • Binds the common signaling IL1R1 IL1RAP ST2 receptor and counteracts both ligands • Induce killing via the immune system (ADCC) Cancer, Inflammation Asthma, Allergy (IL-6 & IL-8
Slide 5: Medical need and IL1RAP
Medical need and IL1RAP 100 Normal cell Cancer cell Frequency pts with IL1RAP CML 80 Colorectal Melanoma AML 60 NSCLC IL1RAP Pancreatic 40 Breast 20 0 Indication • Based on in house data, external data, medical need and market size, NSCLC and pancreatic cancer are primary indications. • Biomarker st
Slide 6: Cantargia at a glance
Cantargia at a glance Current owners (Mar 31, 2018) • Specialized in antibody therapy/immunology, with initial focus on Sunstone 9.0% oncology 1st AP fund 6.9% • Granted IP around therapeutic target and drug candidate • Lead antibody CAN04 in clinical development Avanza Pension 6.2% • Strong managem
Slide 7: Cantargia pipeline
Cantargia pipeline Project Discovery Preclinical Phase | phase phase Phase II Phase III Commercial phase CANO4 Non-small cell lung cancer Pancreatic cancer Leukemia CANxx Autoimmune and inflammatory diseases 7 @antargia
Slide 8: Lead project CAN04 in the highest growth segment – Oncology antibodies
Lead project CAN04 in the highest growth segment– Oncology antibodies CAGR 6.9% CAGR 7.5-10.5% World’s most sold cancer drugs are antibodies 2017 (2016) Immuno-oncology driving market growth 2017 (2016) Rituxan/MabThera $7.87bn ($8.58bn) Opdivo $4.95bn ($3.77bn) Avastin $7.13bn ($6.75bn) Keytruda $3
Slide 9: CAN04 - immuno-oncology mechanism with antitumor effect
CAN04 - immuno-oncology mechanism with antitumor effect Cancer cells Inflammatory C A N 0 4 1 0 m g /k g ( n = 1 0 ) immune cells + N K 1 .1 in t u m o r 2500 20 V e h ic le p = 0 ,0 0 7 2 t u m o r tis s u e Stroma cells T u m o r v o lu m e ( m m ) 3 2000 Is o ty p e c o n tro l Blood vessels 15 C
Slide 10: Inhibition of metastases (tumor cells with low IL1RAP)
Inhibition of metastases (tumor cells with low IL1RAP) Primary tumor Lung metastases 10
Slide 11: Inflammation and metastasis
Inflammation and metastasis • Cancer cells (seeds) needs a good soil to form a metastasis • The IL-1 system (inflammation) can provide such environment (soil) • Cantargia antibody block metastases (presented at American Association of Cancer Research April 16) A tumor can create its own ”seed and so
Slide 12: CANFOUR clinical trial
CANFOUR clinical trial Coordinating Investigator: Professor Ahmad Awada Jules Bordet Institute, Brussels, Belgium Belgium Institut Jules Bordet, Brussels Recruiting Contact: Dr Christiane Jungels Denmark Rigshospitalet, Department of Oncology, Copenhagen Recruiting Contact: Dr Morten Mau Sørensen Th
Slide 13: CANFOUR
CANFOUR Part I • NSCLC, PDAC, CRC, TNBC • Safety and tolerability • Pharmacokinetics • Biomarkers • Efficacy • Identify RP2D Part II • NSCLC, PDAC • Safety and tolerability • Pharmacokinetics • Biomarkers • Efficacy Patients will stay on treatment until disease progression, • Monotherapy unacceptabl
Slide 14: CANTOS additional findings
CANTOS additional findings CANCER decreased risk of death with treatment (high dose) Lung cancer 77 % P=0.0002 Non-lung cancer 37 % P=0.06 Decreased incidence of inflammatory disease (all doses) Arthritis 32% p<0.0001 Ostheoartritis 28% P=0.0005 Gout 53% p<0.0001 Biomarker levels (reduction) CRP 26-
Slide 15: IL1RAP - additional potential indications to leverage the value of our asset
IL1RAP - additional potential indications to leverage the value of our asset • Three different systems signal through IL1RAP • These systems contribute to various inflammatory diseases • Can be blocked by Cantargia’s antibodies against IL1RAP Cantargia partnership with Panorama Res Inc (Sunnyvale, C
Slide 16: Significant value inflection points ahead
Significant value inflection points ahead 2018 • Preclinical data on combination therapy • Clinical progress • Preclinical studies • Phase I clinical data (summer 2018) • Initiation of Phase IIa portion of the clinical trial (summer 2018) • US regulatory and clinical strategy • Application for listi
Slide 17: Cantargia IP
Cantargia IP Use of IL1RAP as target for hematological cancers Valid to 2030 Granted (EPO, USA, Japan, China) Use of IL1RAP as target for solid tumors Valid to 2032 Granted (EPO, Japan, USA, China) The product candidate CAN04 Valid to 2035 Granted EPO, USA New IL1RAP antibodies (e.g. CAN03) Filed 20
Slide 18: Cantargia summary
Cantargia summary • Focus on immuno-oncology - the strongest growing pharmaceutical segment • Taking advantage of established antibody technology to design novel pharmaceuticals • Lead candidate antibody CAN04 in clinical trial • Double mechanism of action • Initial development in NSCLC and pancreat